A Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Oral TT-00420 (Tinengotinib) Tablets in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Prior Treatment of Chemotherapy and FGFR Inhibitor
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Tinengotinib (Primary)
- Indications Biliary cancer; Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors TransThera Biosciences
Most Recent Events
- 27 Dec 2023 Planned End Date changed from 14 Oct 2025 to 31 Oct 2025.
- 27 Dec 2023 Status changed from not yet recruiting to recruiting.
- 05 Oct 2023 New trial record